Chronic Kidney Diseases patients and Kidney Transplant patients. Interferon-Gamma Release Assays, Subclinical Tuberculosis, End-stage Kidney Disease, Detection of Subclinical Tuberculosis, Tuberculosis, IGRAs
Conditions
Interventions
End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation
Screening
End-stage renal disease on renal replacement therapy or status-post-living donor or deceased donor kidney transplantation
Sponsors
National Research Council of Thailand (NRCT)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation 2. Aged more than or equal 18 years
Exclusion criteria
Exclusion criteria: 1. Positive PPD test or a previously documented positive PPD 2. Active pulmonary or extrapulmonary tuberculosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IGRA positivity Baseline Interferon Gamma Releasing Assay | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactPunnee Pitisuttithum
Vaccine Trial Centre, Faculty of Tropical Madicine, Mahidol University
Outcome results
None listed